CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
CROSSJECT

BRIEF

published on 11/14/2025 at 20:51, 20 days 9 hours ago

CROSSJECT Completes €5 Million Financing Deal with Vatel Capital

Convertible Bonds Crossject ZEPIZURE® Vatel Capital €5 Million Financing
PRESS RELEASE

published on 11/14/2025 at 20:46, 20 days 9 hours ago

CROSSJECT completes €5 million financing with Vatel Capital
CROSSJECT announces completion of €5 million financing with Vatel Capital through convertible bonds for ZEPIZURE® development. Funds to support regulatory activities for emergency use authorization application

Financing Convertible Bonds Crossject ZEPIZURE® Vatel Capital
BRIEF

published on 09/24/2025 at 22:05, 2 months 10 days ago

CROSSJECT Reports First Half of 2025 Financial Results and Updates

Financial Results Crossject ZEPIZURE® BARDA Regulatory Progress
PRESS RELEASE

published on 09/24/2025 at 22:00, 2 months 10 days ago

CROSSJECT presents its financial results and key highlights for the first half of 2025
CROSSJECT announces financial results and business highlights for H1 2025, including cash position, R&D investments, BARDA reimbursements, and progress towards ZEPIZURE® registration

Financial Results R&D Investments Crossject ZEPIZURE® BARDA
BRIEF

published on 09/22/2025 at 07:35, 2 months 12 days ago

Additional funding for CROSSJECT from BARDA

FDA Funding Crossject ZEPIZURE® BARDA
PRESS RELEASE

published on 09/22/2025 at 07:30, 2 months 12 days ago

CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
CROSSJECT secures $11.3 million BARDA funding for ZEPIZURE® development towards FDA authorization. Advances include validation batches and facility audit completion

BARDA Funding Crossject FDA Authorization ZEPIZURE Development Emergency Auto-injectors
BRIEF

published on 07/01/2025 at 07:35, 5 months 3 days ago

Change of liquidity contract for CROSSJECT

Liquidity Euronext Pharmaceutical Contract Crossject
BRIEF

published on 06/24/2025 at 19:05, 5 months 10 days ago

CROSSJECT Secures €5.7 Million in Capital Increase

Capital Increase FDA Submission ZEPIZURE® Gemmes Venture Vatel Capital
PRESS RELEASE

published on 06/24/2025 at 19:00, 5 months 10 days ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 5 months 23 days ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior

1 2 ... 6

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 23 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 28 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 58 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 53 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 58 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 27 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 7 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 32 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 43 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 47 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 58 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 13 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 14 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 57 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE